WHO prequalifies Novartis' Coartem Baby for infants
2026-04-24 03:51:48 ET
More on Novartis
- Novartis: Buy Thesis Fades Into Q1 2026 Results (Rating Downgrade)
- Novartis Promises Growth Despite 'Historic' Patent Cliffs - I Broadly Agree
- Novartis: Synnovation Deal And 8% Full-Year 2025 Sales Growth
- Anthropic adds Novartis CEO Narasimhan to board of directors
- Novartis broadens global community health initiatives, aiming to reach over 30 countries by 2030
Read the full article on Seeking Alpha
For further details see:
WHO prequalifies Novartis’ Coartem Baby for infantsNASDAQ: NVS
NVS Trading
-0.26% G/L:
$150.47 Last:
852,043 Volume:
$151.84 Open:



